Compare · SILO vs ZGN
SILO vs ZGN
Side-by-side comparison of Silo Pharma Inc. (SILO) and Ermenegildo Zegna N.V. (ZGN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both SILO and ZGN operate in Apparel (Consumer Discretionary), so they compete in similar markets.
- ZGN is the larger of the two at $3.73B, about 612.6x SILO ($6.1M).
- Over the past year, SILO is down 49.1% and ZGN is up 53.7% - ZGN leads by 102.8 points.
- SILO has been more active in the news (10 items in the past 4 weeks vs 4 for ZGN).
- ZGN has more recent analyst coverage (19 ratings vs 0 for SILO).
- Company
- Silo Pharma Inc.
- Ermenegildo Zegna N.V.
- Price
- $4.83+0.31%
- $13.87-3.95%
- Market cap
- $6.1M
- $3.73B
- 1M return
- -24.28%
- -4.38%
- 1Y return
- -49.13%
- +53.68%
- Industry
- Apparel
- Apparel
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 10
- 4
- Recent ratings
- 0
- 19
Ermenegildo Zegna N.V.
Ermenegildo Zegna N.V., together with its subsidiaries, designs, manufactures, markets, and distributes luxury menswear, footwear, leather goods, and other accessories under the Zegna and the Thom Browne brands. It provides luxury leisurewear for men; formal suits, tuxedos, shirts, blazers, formal overcoats, and accessories; leather accessories comprising shoes, bags, belts, and small leather accessories; and fragrances. The company also offers luxury womenswear and childrenswear under the Thom Browne brand, as well as provides eyewear, cufflinks and jewelry, watches, underwear, and beachwear manufactured by third parties under licenses. It serves customers through its retail stores and online channels in Europe, the Middle East, Africa, North America, Latin America, the Asia Pacific, and internationally. The company was founded in 1910 and is based in Trivero, Italy. Ermenegildo Zegna N.V. is a subsidiary of Monterubello Societa' Semplice.
Latest SILO
- SEC Form D filed by Silo Pharma Inc.
- Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform
- Silo Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
- Silo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
- SEC Form SCHEDULE 13G filed by Silo Pharma Inc.
- Silo Pharma Subsidiary QwikAgents Set to Advance Enterprise AI Agent Platform through NVIDIA Developer Program
- SEC Form DEFA14A filed by Silo Pharma Inc.
- SEC Form DEF 14A filed by Silo Pharma Inc.
- Silo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting Request
- Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial
Latest ZGN
- SEC Form 6-K filed by Ermenegildo Zegna N.V.
- SEC Form 3 filed by new insider Hamiyeh Nagi Adel
- SEC Form 6-K filed by Ermenegildo Zegna N.V.
- Ermenegildo Zegna Group Reports Voting Results of the Annual General Meeting Held on June 26, 2026
- Zegna Group downgraded by Goldman with a new price target
- Zegna Group upgraded by TD Cowen with a new price target
- SEC Form SD filed by Ermenegildo Zegna N.V.
- Artistic Director Sartori Alessandro converted options into 31,500 units of Ordinary Shares and sold $85,346 worth of Ordinary Shares (6,505 units at $13.12), increasing direct ownership by 21% to 142,237 units (SEC Form 4) to satisfy withholding tax
- Group Chief Financial Officer Santhia Gian Franco sold $75,676 worth of Ordinary Shares (5,768 units at $13.12) and converted options into 15,600 units of Ordinary Shares, increasing direct ownership by 28% to 44,448 units (SEC Form 4) (tax liability)
- Co-CEO of the ZEGNA brand Zegna Di Monte Rubello Edoardo converted options into 31,500 units of Ordinary Shares and sold $223,525 worth of Ordinary Shares (17,037 units at $13.12), increasing direct ownership by 5% to 304,960 units (SEC Form 4) (for tax liability)